Archives

  • 2026-07
  • 2026-06
  • 2026-05
  • 2026-04
  • 2026-03
  • 2026-02
  • 2026-01
  • 2025-12
  • 2025-11
  • 2025-10
  • 2023-07
  • 2023-06
  • 2023-05
  • 2023-04
  • 2023-03
  • 2023-02
  • 2023-01
  • 2022-12
  • 2022-11
  • 2022-10
  • 2022-09
  • 2022-08
  • 2022-07
  • 2022-06
  • 2022-05
  • 2022-04
  • 2022-03
  • 2022-02
  • 2022-01
  • 2021-12
  • 2021-11
  • 2021-10
  • 2021-09
  • 2021-08
  • 2021-07
  • 2021-06
  • 2021-05
  • 2021-04
  • 2021-03
  • 2021-02
  • 2021-01
  • 2020-12
  • 2020-11
  • 2020-10
  • 2020-09
  • 2020-08
  • 2020-07
  • 2020-06
  • 2020-05
  • 2020-04
  • 2020-03
  • 2020-02
  • 2020-01
  • 2019-12
  • 2019-11
  • 2019-10
  • 2019-09
  • 2019-08
  • 2019-07
  • 2019-06
  • 2019-05
  • 2019-04
  • 2018-11
  • 2018-10
  • 2018-07

    • DRP1 Activation Drives Mitochondrial Fission and Glycolysis

    2026-07-04

    DRP1 Activation Drives Mitochondrial Fission and Glycolytic Shift in ATII Cells Under Hyperoxia

    Study Background and Research Question

    Bronchopulmonary dysplasia (BPD) remains a leading complication among preterm infants, especially those with birth weights under 1500 g, with incidences reaching up to 30% (Sun et al., 2024). BPD is characterized by impaired alveolar development and chronic lung injury, leading to substantial morbidity and healthcare burden. Mitochondrial damage and metabolic reprogramming, particularly in alveolar type II (ATII) cells, have been increasingly recognized as central to BPD pathogenesis. However, the precise interplay between mitochondrial dynamics—specifically fission/fusion events—and glucose metabolism in ATII cells under hyperoxic stress has not been fully elucidated. This study by Sun et al. addresses this knowledge gap by investigating how the mitochondrial fission protein DRP1 regulates metabolic reprogramming in ATII cells during hyperoxic exposure.

    Key Innovation from the Reference Study

    The principal innovation of Sun et al. (2024) lies in uncovering a direct mechanistic link between DRP1-mediated mitochondrial fission and a glycolytic shift in ATII cells subjected to hyperoxia. The authors demonstrate that DRP1 activation not only triggers changes in mitochondrial morphology but also induces the upregulation of glycolysis-related enzymes, driving a metabolic shift toward aerobic glycolysis. Importantly, the study shows that pharmacological inhibition of DRP1 reverses both mitochondrial fragmentation and glycolytic enhancement, suggesting a causative role for DRP1 signaling in the metabolic dysregulation observed in hyperoxic lung injury. This work extends the concept of metabolic reprogramming—previously well-characterized in cancer and hypoxic adaptation—into the context of neonatal lung disease.

    Methods and Experimental Design Insights

    To dissect the relationship between mitochondrial dynamics and glucose metabolism in BPD, the research team employed a multi-faceted experimental approach:

    • Animal Model: Neonatal rats were exposed to either 85% oxygen (hyperoxia) or 21% oxygen (control) across developmental timepoints (postnatal days 3, 7, 10, 14). This in vivo model recapitulates key features of human BPD.
    • Histopathology: Hematoxylin and eosin (HE) staining was performed to assess lung tissue damage and alveolar structure.
    • Protein Expression Analysis: Immunohistochemistry (IHC), immunofluorescence assay, and Western blotting were used to measure DRP1, phosphorylated DRP1 (p-DRP1), and glycolytic enzymes (PFKM, HK2, LDHA) in lung tissues and isolated ATII cells.
    • Metabolic Flux Measurements: Seahorse XF96 analysis enabled real-time quantification of extracellular acidification rate (ECAR) and oxygen consumption rate (OCR) as proxies for glycolysis and oxidative phosphorylation, respectively.
    • ATP Quantification: Cellular ATP levels were measured using a commercial ATP kit.
    • Pharmacological Intervention: The mitochondrial fission inhibitor Mdivi-1 was applied to RLE-6TN cells under hyperoxic conditions to assess the functional role of DRP1 in metabolism and mitochondrial morphology.
    • Co-localization Studies: Double immunofluorescence staining was employed to confirm the spatial association of DRP1 with ATII cell markers, enhancing confidence in cell-type-specific observations.

    Protocol Parameters

    • Hyperoxia exposure: Neonatal rats were exposed to 85% O2 continuously for up to 14 days postnatally to induce lung injury.
    • Primary cell isolation: ATII cells were isolated from lung tissue for downstream metabolic and protein expression analyses.
    • Mdivi-1 treatment: RLE-6TN cells were treated with Mdivi-1 (a DRP1 inhibitor) under 85% O2 for 48 hours to probe the effects of DRP1 blockade on glycolysis and mitochondrial morphology.
    • Immunofluorescence protocols: Double immunolabeling was used to visualize DRP1 and ATII cell markers, supporting cell-specific localization.

    Core Findings and Why They Matter

    The study establishes several critical findings:

    • Mitochondrial Morphology: Hyperoxia caused pronounced mitochondrial fragmentation in ATII cells, indicating enhanced fission.
    • DRP1 Activation: Both total DRP1 and its phosphorylated (active) form were significantly upregulated in lung tissue and ATII cells following hyperoxia.
    • Glycolytic Shift: Key glycolytic enzymes (PFKM, HK2, LDHA) were markedly increased under hyperoxic conditions, consistent with a switch to aerobic glycolysis (the Warburg effect).
    • Decreased ATP Production: Despite increased glycolytic activity, ATP levels were suppressed in hyperoxic ATII cells, reflecting inefficient energy metabolism.
    • Functional Reversal with Mdivi-1: Inhibition of DRP1 with Mdivi-1 reversed mitochondrial fragmentation and normalized glycolytic enzyme expression, confirming the central role of DRP1-driven fission in metabolic reprogramming.

    These findings deepen our understanding of how mitochondrial dynamics control metabolic state in the developing lung. The demonstration that DRP1 inhibition can mitigate both structural and metabolic pathologies highlights this pathway as a promising therapeutic target for BPD and potentially other conditions involving dysfunctional mitochondrial fission.

    Comparison with Existing Internal Articles

    Several internal resources discuss the practical aspects of Cy3 Goat Anti-Rabbit IgG (H+L) Antibody in immunofluorescence and related assays:

    In contrast to these application-oriented articles, Sun et al. provide a mechanistic framework connecting mitochondrial fission and metabolic shifts, with immunofluorescence serving as an essential tool for cellular localization. The internal resources complement the reference study by offering practical workflows and troubleshooting strategies for achieving robust, reproducible immunofluorescence results using Cy3-conjugated secondary antibodies.

    Limitations and Transferability

    While the findings of Sun et al. significantly advance our mechanistic understanding of BPD, several limitations should be noted:

    • Species and Model Constraints: The study relies on a neonatal rat model, which recapitulates many but not all aspects of human BPD. Differences in lung development and oxygen sensitivity may influence transferability to clinical settings.
    • Cell Line Versus Primary Cells: Some experiments were conducted in RLE-6TN cells, a rat lung epithelial cell line, which may not fully reflect the properties of primary ATII cells in vivo.
    • Pharmacological Specificity: Mdivi-1, while a widely used DRP1 inhibitor, may have off-target effects. Thus, genetic approaches could further validate the specificity of results.
    • Temporal Scope: The study focuses on early postnatal timepoints; long-term consequences of DRP1 modulation remain to be explored.

    Nevertheless, the central role of DRP1 in coordinating mitochondrial and metabolic responses under oxidative stress is likely relevant across multiple tissues and disease contexts, making these findings broadly informative for studies of organ injury, metabolic disease, and mitochondrial pharmacology.

    Research Support Resources

    For researchers aiming to reproduce or extend the immunofluorescence and immunohistochemistry workflows exemplified in this study, the Cy3 Goat Anti-Rabbit IgG (H+L) Antibody (SKU K1209) from APExBIO offers robust signal amplification and high specificity for rabbit primary antibodies. This Cy3-conjugated secondary antibody is well-suited for sensitive detection in co-localization and metabolic enzyme expression studies, aligning with methodologies reported by Sun et al. For further workflow optimization and troubleshooting, researchers may consult scenario-driven guidance available in internal application articles such as "Optimizing Cell-Based Assays with Cy3 Goat Anti-Rabbit Ig..." and related resources.